Career Center

SoMCC Event

Title:

  The Science & Business of Drug Development: How to Make the Most out of Research and Discovery
Date:   Wednesday, October 10, 2007
Time:   12:00 -1:00 PM (Presentation and Q&A)
1:00-1:30 PM (Informal reception)

Location:   Clark Center Auditorum

Sponsor:   School of Medicine Career Center (SoMCC)

Event details:  


Overview:   
The drug development process, from early stage research and discovery to regulatory approval, is a long and expensive one.  The costs associated with this process are a primary factor in the high and rising cost of healthcare in the US and other places.  At the same time, demand remains strong among patients for safe and efficacious therapies designed to treat their specific conditions.  So is it possible for a given company to spend less money, sustain profits, and continue to develop drugs to meet the needs of patients, and what are some of the roles for researchers and clinicians in addressing these challenges?

As a leader in drug development, Genentech has proven to be remarkably adept in adapting to both scientific and business shifts throughout the years.  The company relies upon the expertise of researchers and clinicians for insights pertaining to their own specific fields, as well as a balanced understanding and recognition of the priorities and objectives established by the company.  As such, their input and expertise is critical to senior management in identifying and advancing the most promising areas for further development and continued investment.  This seminar provides a unique opportunity to gain first-hand insights, based on the experiences of an accomplished scientist-executive at Genentech, into the following:

• With so many research projects happening at once, how to evaluate which ones to keep/drop?
• What are the steps/stages for establishing alliance/partnership contracts, and forms this can take?
• What are the greatest challenges (scientific and business) associated with pipeline planning?
• What does it take to successfully transition from academic to industrial biotechnology?

About the Speaker:
Ashraf Hanna joined Genentech in 2006, and is the Vice President, Alliance Management & Portfolio Planning.  As such, he is responsible for Genentech’s collaborations with other companies and helping Genentech appropriately assess and plan its drug portfolio.  Ashraf brings more than 13 years of professional experience in biotech, as a physician and with the consulting firm McKinsey and Company.  Prior to joining Genentech, Ashraf served as Vice President of Strategic Planning and Business Development with Tanox, Inc. 

Ashraf has a Ph.D. in Physics from Harvard University, and an M.D. from the University of Massachusetts.

Fee:  
Free and open to Stanford ID holders.
     
Additional information and/or registration:   RSVP required. Space is limited, register online

Stanford Medicine Resources:

Footer Links: